See more : Schroder Real Estate Investment Trust Limited (SREI.L) Income Statement Analysis – Financial Results
Complete financial analysis of Algernon Pharmaceuticals Inc. (AGNPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Algernon Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Compucom Software Limited (COMPUSOFT.BO) Income Statement Analysis – Financial Results
- Pretium Resources Inc. (PVG) Income Statement Analysis – Financial Results
- Atlantic Coastal Acquisition Corp. (ACAHW) Income Statement Analysis – Financial Results
- Rovsing A/S (ROV.CO) Income Statement Analysis – Financial Results
- Woodstock Holdings, Inc. (WSFL) Income Statement Analysis – Financial Results
Algernon Pharmaceuticals Inc. (AGNPF)
About Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 50.40K | 34.94K | 0.00 | 0.00 | 27.00K | 40.95K | 127.54K | 47.96K | 0.00 |
| Gross Profit | -50.40K | -34.94K | 0.00 | 0.00 | -27.00K | -40.95K | -127.54K | -47.96K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.08M | 2.29M | 4.80M | 2.68M | 605.73K | 93.82K | 354.47K | 195.49K | 181.38K |
| General & Administrative | 2.68M | 3.00M | 2.46M | 4.72M | 1.07M | 854.74K | 1.03M | 2.30M | 549.09K |
| Selling & Marketing | 1.26M | 729.80K | 794.32K | 1.27M | 234.03K | 0.00 | 62.58K | 436.61K | 0.00 |
| SG&A | 3.94M | 3.73M | 3.25M | 5.99M | 1.31M | 854.74K | 1.10M | 2.74M | 549.09K |
| Other Expenses | 0.00 | 0.00 | 305.12K | 16.05K | 0.00 | 0.00 | 0.00 | -3.95M | 0.00 |
| Operating Expenses | 5.02M | 6.02M | 8.05M | 8.66M | 1.91M | 948.56K | 1.45M | 2.93M | 730.47K |
| Cost & Expenses | 5.02M | 6.02M | 8.05M | 8.66M | 1.91M | 948.56K | 1.45M | 2.93M | 730.47K |
| Interest Income | 2.10K | 2.08K | 11.93K | 35.08K | 6.72K | 10.96K | 7.25K | 7.17K | 0.58 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 50.40K | 34.94K | 7.88M | 27.00K | 27.00K | 40.95K | 127.54K | 47.96K | 730.47K |
| EBITDA | -4.98M | -5.95M | 0.00 | -8.42M | -1.90M | -858.18K | -1.27M | -2.77M | 579.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.02M | -5.98M | -8.05M | -8.75M | -1.93M | -948.56K | -1.01M | -2.93M | -730.47K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.76M | 63.28K | 2.11M | 858.46K | -102.32K | -38.46K | -496.26K | -3.94M | 579.00 |
| Income Before Tax | -6.78M | -6.05M | -7.73M | -8.54M | -1.90M | -937.59K | -1.89M | -6.88M | -729.89K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 34.40K | -19.80K | -122.87K | -18.34K | -120.19K | 438.64K | -7.17K | 0.58 |
| Net Income | -6.78M | -6.05M | -7.73M | -8.54M | -1.90M | -937.59K | -1.89M | -6.88M | -729.89K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.45 | -0.73 | -1.04 | -2.03 | -0.89 | -0.70 | -1.54 | -8.17 | -3.49 |
| EPS Diluted | -0.45 | -0.73 | -1.04 | -2.03 | -0.89 | -0.70 | -1.54 | -8.17 | -3.48 |
| Weighted Avg Shares Out | 15.15M | 8.30M | 7.44M | 4.21M | 2.13M | 1.34M | 1.23M | 841.79K | 209.00K |
| Weighted Avg Shares Out (Dil) | 15.15M | 8.30M | 7.44M | 4.21M | 2.13M | 1.34M | 1.23M | 841.79K | 209.99K |
Algernon Announces Warrant Extension
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES
Algernon Pharmaceuticals Announces Closing of Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces Increase to Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces Closing of Private Placement
VANCOUVER, British Columbia, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces the close of its non-brokered private placement, previously announced on July...
Algernon Pharmaceuticals Announces Increase to Private Placement
VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced on July...
Algernon Pharmaceuticals Announces Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical...
Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services
VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has engaged the services of...
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro),...
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to invite investors and other interested parties to participate in an upcoming special CEO interview and Q...
Source: https://incomestatements.info
Category: Stock Reports